ZAI LAB

9688
19.1805.24% ( -1.060 )
Delay Closed: Nov 16, 16:08:11

Overview

ZAI LAB (9688)

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of o...

Open
19.800
High
19.800
Low
19.100
Prev. Close
20.240
Volume
6.84M
Turnover
131.79M
Avg Price
19.270
Bid/Ask Ratio
-92.81%
Amplitude
3.46%
52wk High
21.500
Volume Ratio
1.00
Turnover Ratio
0.54%
52wk Low
12.310
HK Mkt Cap
24.13B
Market CapHKD
24.13B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.24
EPSDynamic
-1.23
EPSStatic
--
BVPS
3.51
P/B
5.46
HK Shares
1.26B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.26B
Min lot size
100
Currency
HKD

ZAI LAB Analyst Rating

View more

Forecast & Rating

Nov 5, 2026
Price forecast
HK$21.049.68%
Forecast & RatingBuy
9analysts
  • Strong buy55.56%
  • Buy22.22%
  • Hold22.22%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Zai Lab fell 5.24% to HK$19.18, gapping down from HK$20.24 and fading from an intraday HK$19.67 to a 13:02 low of HK$19.10, on 6.68 million shares and HK$129 million turnover. The pullback is anchored in Q3 2026 results: revenue of HK$849 million slipped 6.02% year on year, net loss widened 29.35% to HK$362 million, net margin was -42.64% and loss per share HK$0.3222, with profit-taking following the 52-week high of HK$21.50 set on 9 November. Pipeline news ran the other way: KarXT and VYVGART Hytrulo won first-time inclusion in China's 2026 national reimbursement list, ZL-1503 (IL-13/IL-31R alpha bispecific) showed rapid, sustained biomarker inhibition in Phase 1, and Zoci reported a 40% response rate in extrapulmonary neuroendocrine carcinoma as it advances into global Phase III. The stock is still up 41.24% year to date, 10.79% below its 52-week high and 55.81% above the February low of HK$12.31, holding above the MA20 of HK$18.82 but below the MA60 of HK$19.50, with PB 5.46 and a negative PE of -15.51. Though reimbursement uptake and later-stage readouts are still to be delivered.

  2. Nov, 11

    Zai Lab closed down 4.3% at HK$20.56 in a spike-and-fade session: it touched HK$20.72 in the morning, slid to HK$20.16 by 13:17 and recovered only late, after Q3 revenue of HK$849 million fell 6.02% y/y and net loss widened 29.35% to HK$362 million at a -42.6% net margin, with employee option and RSU grants adding share count; the advance tied to Zoci's global Phase III entry unwound from the HK$21.50 52-week high set on 9 November. The stock still sits above MA20 of HK$18.50 and MA60 of HK$19.50, up 51.4% YTD, 4.37% below the 52-week high and 67.0% above the February low of HK$12.31. Though the US$249.93 million ADS private placement completed in September funds the pipeline.

  3. Nov, 9

    Zai Lab extended its advance, dipping to HK$20.00 in early trade before climbing to an intraday high of HK$21.04 at 10:45 and closing at HK$20.96 after a high-level afternoon range, with gains at one point exceeding 10% on 10.23 million shares worth HK$212 million and a 0.82% turnover rate. The move was driven by third-quarter product revenue of US$107.6 million and the advance of proprietary ADC Zoci into a global Phase III trial in extrapulmonary neuroendocrine carcinoma, alongside a broad innovative-drug sector rally. The stock now sits above its MA20 of HK$18.32 and MA60 of HK$19.47, up 54.34% year to date and just 2.15% below its 52-week high of HK$21.42. Though losses for the first nine months widened to nearly US$148 million, including US$46.14 million in the third quarter, with a PE of -16.85, leaving the balance between commercialization and R&D spending unproven.

  4. Nov, 4

    Zai Lab opened lower but rallied to close at the day's high of HK$18.01, up 6.76% from HK$16.87, on 5.216 million shares worth HK$92.03 million, after ESMO data showed Zoci plus atezolizumab delivered an 81.8% objective response rate in first-line extensive-stage small cell lung cancer phase 1b, which the company said supports a phase 3 programme, alongside the closing of a US$249.93 million ADS private placement. The stock held HK$17.12 in the morning session, touched HK$17.48, then trended up through the afternoon to HK$18.01. It is up 32.62% year to date yet still 15.92% below its 52-week high of HK$21.42 set on 19 August, and trades under its MA20 of HK$18.36 and MA60 of HK$19.49. While Q2 2026 revenue fell 3.42% year on year to HK$833.8 million and the net loss widened 24.68% to HK$398.6 million at a -47.81% net margin, with PB at 4.73 and PE negative.

  5. Oct, 26

    Driven by ESMO data for Zoci plus atezolizumab in first-line ES-SCLC, Zai Lab 9688.HK rose more than 7% intraday and closed at HK$18.77 after a high-open, dip-and-rebound session. The 1b study showed an 81.8% objective response rate, the direct catalyst. Still, the latest two quarters showed revenue down 5.74% and 3.42% year over year, net losses of HK$400 million and HK$399 million, and EPS of -HK$0.3612 and -HK$0.3569, with losses widening year over year. The stock is up 38.22% year to date but remains 20.67% below its 52-week high of HK$23.66 and under MA20 of 19.199 and MA60 of 19.209; the earlier 11.34 million ADS placement raising nearly HK$1.9 billion, about 9% dilution, remains an offset.

News

Bullish vs. Bearish — Last 3 Months

4.2k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • P
    Profit

    Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.

    JD Health, a leader in internet healthcare, continues to see growth in monthly active users and online penetration of prescription drugs. Improved consumer sentiment post-ceasefire is beneficial for platform transaction volume.

    Insilico Medicine is a globally representative company in AI-driven drug discovery, with pipeline progress being a short-term catalyst. Its latest funding round valued the company at over $600 million, and it is currently in a window of valuation re-rating as it transitions from an AI tool provider to a clinical-stage pipeline company.

  • M
    momoM

    $Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticals

    mp.weixin.qq.com/s/gihUP-...

    当前环境异常,完成验证后即可继续访问。

    当前环境异常,完成验证后即可继续访问。

    mp.weixin.qq.com